Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 12/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 10/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.65 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.65 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.62 |
| ▸ | TNF | P01375 | 1/20 | 0.62 |
| ▸ | IL1B | P01584 | 1/20 | 0.62 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.62 |
| ▸ | STAT3 | P40763 | 2/20 | 0.62 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29856029 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL19451294 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL22280101 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL24142128 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL19451416 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884378 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL17873760 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL23884163 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| SCHEMBL21814694 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 | |
| Hydrochloric Acid SCHEMBL30510193 | 0.99 | CRBN (0.68) | CRBNDDB1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734989-A2 | SYNTHESIS AND IN VITRO CHARACTERIZATION OF PROTEOLYSIS TARGETING CHIMERAS (PROTACS) FOR DEGRADATION OF DNA METHYLTRANSFERASE 1 (DNMT1) | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4736882-A2 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | Cullgen (Shanghai), Inc. (CN) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3841098-B1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2026-01-14 | — | — | EP | disclosed |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| WO-2025216628-A1 | PROTAC COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2025-10-16 | — | — | WO | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | CULLGEN (SHANGHAI), INC. (CN) | 2025-09-09 | — | — | US | disclosed |
| WO-2018081530-A1 | COMPOSITIONS AND METHODS FOR TREATING EZH2-MEDIATED CANCER | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-3256470-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | Dana Farber Cancer Institute, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2017204445-A2 | PHARMACEUTICAL COMPOSITION INDUCING DECOMPOSITION OF ALK PROTEIN, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE COMPONENT | 한국화학연구원 | 2017-11-30 | — | — | WO | disclosed |
| WO-2017180417-A1 | BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176957-A1 | MDM2 PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017176958-A1 | MONOFUNCTIONAL INTERMEDIATES FOR LIGAND-DEPENDENT TARGET PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017024317-A2 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016105518-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885HDAC1 502/4885 |
| US-12410171-B2 | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use | MUSK, ERBB2, NTRK1 | CRBN 330/4885DDB1 480/4885HDAC1 1716/4885 |
| US-20250388587-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | ERBB2, MUSK, ERBB3 | CRBN 149/4885DDB1 1222/4885HDAC1 778/4885 |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | CRBN 109/4885DDB1 75/4885HDAC1 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.